Imunon, Inc. (IMNN)
1.59
-0.05
(-3.05%)
USD |
NASDAQ |
Aug 24, 16:00
1.604
+0.01
(+0.88%)
After-Hours: 20:00
Imunon Enterprise Value : 8.399M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 8.399M |
| August 21, 2026 | 8.633M |
| August 20, 2026 | 8.353M |
| August 19, 2026 | 8.353M |
| August 18, 2026 | 8.353M |
| August 17, 2026 | 8.446M |
| August 14, 2026 | 8.679M |
| August 13, 2026 | 8.353M |
| August 12, 2026 | 8.493M |
| August 11, 2026 | 8.493M |
| August 10, 2026 | 8.586M |
| August 07, 2026 | 8.493M |
| August 06, 2026 | 8.353M |
| August 05, 2026 | 8.399M |
| August 04, 2026 | 8.773M |
| August 03, 2026 | 8.353M |
| July 31, 2026 | 8.399M |
| July 30, 2026 | 8.446M |
| July 29, 2026 | 8.166M |
| July 28, 2026 | 8.119M |
| July 27, 2026 | 8.119M |
| July 24, 2026 | 8.026M |
| July 23, 2026 | 8.726M |
| July 22, 2026 | 8.399M |
| July 21, 2026 | 8.773M |
| Date | Value |
|---|---|
| July 20, 2026 | 9.239M |
| July 17, 2026 | 9.519M |
| July 16, 2026 | 9.799M |
| July 15, 2026 | 9.986M |
| July 14, 2026 | 10.17M |
| July 13, 2026 | 10.13M |
| July 10, 2026 | 10.41M |
| July 09, 2026 | 10.36M |
| July 08, 2026 | 10.59M |
| July 07, 2026 | 10.08M |
| July 06, 2026 | 10.22M |
| July 02, 2026 | 9.892M |
| July 01, 2026 | 9.752M |
| June 30, 2026 | 9.286M |
| June 29, 2026 | 3.179M |
| June 26, 2026 | 3.140M |
| June 25, 2026 | 2.865M |
| June 24, 2026 | 2.904M |
| June 23, 2026 | 3.100M |
| June 22, 2026 | 3.179M |
| June 18, 2026 | 3.257M |
| June 17, 2026 | 3.414M |
| June 16, 2026 | 3.493M |
| June 15, 2026 | 3.767M |
| June 12, 2026 | 4.042M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Phio Pharmaceuticals Corp. | 0.5961M |
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 283.25B |
| Anika Therapeutics, Inc. | 272.43M |
| BioCryst Pharmaceuticals, Inc. | 2.955B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.814M |
| Total Expenses (Quarterly) | 2.814M |
| EPS Diluted (Quarterly) | -0.5412 |
| Earnings Yield | -241.7% |
| Normalized Earnings Yield | -241.87 |